<DOC>
	<DOC>NCT02559687</DOC>
	<brief_summary>In this study participants with advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type I adenocarcinoma of the gastroesophageal junction (GEJ) previously treated with two standard therapies will be treated with pembrolizumab</brief_summary>
	<brief_title>Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy greater than 3 months Histologicallyproven advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ Documented objective radiographic or clinical disease progression on two previous lines of standard therapy Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 Can provide either a newly obtained or archival tumor tissue sample for intratumoral immunerelated testing and for antiprogrammed cell death (PD1) Female participants of childbearing potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of study medication Male participants must agree to use adequate contraception starting with the first dose through 120 days after the last dose of study medication Adequate organ function Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medication Has active autoimmune disease that has required systemic treatment within the 2 years prior to the first dose of study medication Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication Known central nervous system (CNS) metastases and/or carcinomatous meningitis Prior anticancer mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study medication or not recovered from adverse events due to a previously administered agent Prior therapy with a PD1, antiPDLigand 1 (PDL1), or antiPDL2 agent, or previously participated in a Merck pembrolizumab (MK3475) study Has a known additional malignancy that has progressed or required active treatment within the last 5 years with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, insitu cervical cancer, and insitu or intramucosal pharyngeal cancer Received a live vaccine within 30 days of the first dose of study medication Known history of Human Immunodeficiency Virus (HIV) infection Known active Hepatitis B or C History of noninfectious pneumonitis that required steroids or current pneumonitis Active infection requiring systemic therapy Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
</DOC>